123 related articles for article (PubMed ID: 2906459)
41. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
[TBL] [Abstract][Full Text] [Related]
42. Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan.
Inoue M
Drugs; 1988; 35 Suppl 3():114-9. PubMed ID: 2905239
[TBL] [Abstract][Full Text] [Related]
43. Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats.
Umegaki E; Yoda Y; Tokioka S; Murano M; Higuchi K
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S35-40. PubMed ID: 20586863
[TBL] [Abstract][Full Text] [Related]
44. Effect of roxatidine acetate on daytime and night-time peptone-stimulated gastric acid secretion.
Hagenmüller F
Drugs; 1988; 35 Suppl 3():65-8. PubMed ID: 2905251
[TBL] [Abstract][Full Text] [Related]
45. Regular use of H2 blockers reduces the efficacy of roxatidine to control gastric pH and volume.
Hirota K; Kudo M; Kushikata T; Hashimoto H; Matsuki A
Can J Anaesth; 2005 Feb; 52(2):166-71. PubMed ID: 15684257
[TBL] [Abstract][Full Text] [Related]
46. [Clinical evaluation of roxatidine acetate hydrochlorides as a preanesthetic medication].
Namba M; Chihara E; Ibuki T; Ashida H; Fukushima H; Tanaka Y
Masui; 2001 Feb; 50(2):127-35. PubMed ID: 11244765
[TBL] [Abstract][Full Text] [Related]
47. [Effective prevention of indomethacin-induced gastroduodenal mucosal lesions with roxatidine acetate].
Dammann HG; Wolf N; Burkhardt F
Arzneimittelforschung; 1995 Aug; 45(8):880-2. PubMed ID: 7575752
[TBL] [Abstract][Full Text] [Related]
48. Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double-blind controlled multicentre study in Singapore.
Fock KM; Kang JY; Ng HS; Ng TM; Gwee KA; Lim CC
J Gastroenterol Hepatol; 1995; 10(4):379-82. PubMed ID: 8527701
[TBL] [Abstract][Full Text] [Related]
49. Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation.
Lee M; Lee NY; Chung KS; Cheon SY; Lee KT; An HJ
Sci Rep; 2017 Jan; 7():41721. PubMed ID: 28139747
[TBL] [Abstract][Full Text] [Related]
50. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages.
Cho EJ; An HJ; Shin JS; Choi HE; Ko J; Cho YW; Kim HM; Choi JH; Lee KT
J Cell Biochem; 2011 Dec; 112(12):3648-59. PubMed ID: 21809375
[TBL] [Abstract][Full Text] [Related]
51. The use of roxatidine acetate in fasting patients prior to induction of anaesthesia as prophylaxis against the acid aspiration syndrome.
Tryba M; Wruck G; Thole H; Zenz M
Drugs; 1988; 35 Suppl 3():20-4. PubMed ID: 2905245
[TBL] [Abstract][Full Text] [Related]
52. Roxatidine acetate as maintenance treatment for patients with peptic ulcer disease. The European Cooperative Roxatidine Study Group.
Clin Ther; 1991; 13(1):47-57. PubMed ID: 1674231
[TBL] [Abstract][Full Text] [Related]
53. A comparison of roxatidine acetate and ranitidine in duodenal ulcer healing.
Hüttemann W
Drugs; 1988; 35 Suppl 3():90-5. PubMed ID: 2905255
[TBL] [Abstract][Full Text] [Related]
54. Roxatidine versus ranitidine in the treatment of duodenal ulcer: a randomized, double blind, controlled, multicenter study in Thailand.
Kachintorn U; Chinapak O; Vongphanich V; Kositchaiwat C; Lekhayananda S; Khow-ean U; Suttinont C; Saowaros V; Kludchareon N; Leethochawalit M
J Med Assoc Thai; 1995 Dec; 78(12):641-7. PubMed ID: 8868007
[TBL] [Abstract][Full Text] [Related]
55. Ritanserin assessments in plasma and CSF by means of HPLC technique with fluorescence detection.
Larsson M; Forsman A
Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):349-51. PubMed ID: 2888936
[TBL] [Abstract][Full Text] [Related]
56. Roles of extracellular Ca++ and calmodulin in roxatidine-stimulated secretion and synthesis of mucus by cultured rabbit gastric mucosal cells.
Takahashi S; Okabe S
J Pharmacol Exp Ther; 1998 Jan; 284(1):37-42. PubMed ID: 9435158
[TBL] [Abstract][Full Text] [Related]
57. Clinical characteristics of roxatidine acetate: a review.
Dammann HG; de Looze SM; Bender W; Labs R
Scand J Gastroenterol Suppl; 1988; 146():121-34. PubMed ID: 2906456
[TBL] [Abstract][Full Text] [Related]
58. The effects of roxatidine on neuromuscular transmission.
Bossa R; Chiericozzi M; Galatulas I; Salvatore G; Teli M; Baggio G; Castelli M
In Vivo; 1995; 9(2):113-5. PubMed ID: 7548786
[TBL] [Abstract][Full Text] [Related]
59. Paracetamol (acetaminophen) penetrates readily into the cerebrospinal fluid of children after intravenous administration.
Kumpulainen E; Kokki H; Halonen T; Heikkinen M; Savolainen J; Laisalmi M
Pediatrics; 2007 Apr; 119(4):766-71. PubMed ID: 17403848
[TBL] [Abstract][Full Text] [Related]
60. Interaction of roxatidine acetate with antacids, food and other drugs.
Labs RA
Drugs; 1988; 35 Suppl 3():82-9. PubMed ID: 2905254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
